Targeting 'monster cancer cells' could reduce recurrence rates after cancer therapy retrieved 28 May 2024 from https://medicalxpress.com/news/2024-05-monster-cancer-cells-recurrence-therapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Belfast mum diagnosed with cancer after noticing 'odd-looking spot'Lyn's skin cancer was detected by the Action Cancer's skin cancer detection service
Source: BelfastLive - 🏆 16. / 77 Read more »
Study finds targeting BET and OXPHOS causes synthetic lethality in liver cancerPrimary hepatocellular carcinoma (HCC), the major type of liver cancer, is a leading cause of worldwide cancer-related death. End-stage liver cancer patients have limited treatment options due to the lack of druggable targets, and the treatment outcome is usually complicated by the heterogeneous tumor microenvironment.
Source: medical_xpress - 🏆 101. / 51 Read more »
Targeting protein interactions may boost antitumor immunity in breast cancerA multi-institutional team of investigators has discovered that targeting a specific protein interaction within immunosuppressive breast cancer cells may increase antitumor immune responses in otherwise difficult to treat solid tumors, according to recent findings published in the Journal of Clinical Investigation.
Source: medical_xpress - 🏆 101. / 51 Read more »
FDA-approved TIVDAK®: Targeting tissue factor in cervical cancerOn April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Source: NewsMedical - 🏆 19. / 71 Read more »
Latest advances in gastric cancer and other cancer-related studies to be presented at DDW 2024Cancer-related studies, including a diagnostic tool for gastric cancer and trends in gallbladder and colorectal cancers, will be presented this week at Digestive Disease Week (DDW) 2024.
Source: NewsMedical - 🏆 19. / 71 Read more »
Proximity to a cancer center contributes to cancer stage at diagnosis, study findsLocation, race and insurance status play a significant part in the odds of a patient being diagnosed with early-stage or late-stage cancer, according to a detailed medical records analysis of more than 94,000 patients with cancer by researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center.
Source: medical_xpress - 🏆 101. / 51 Read more »